Rebecka Hellsten

831 total citations
23 papers, 649 citations indexed

About

Rebecka Hellsten is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Rebecka Hellsten has authored 23 papers receiving a total of 649 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Rebecka Hellsten's work include Cytokine Signaling Pathways and Interactions (11 papers), Prostate Cancer Treatment and Research (6 papers) and Microbial Natural Products and Biosynthesis (4 papers). Rebecka Hellsten is often cited by papers focused on Cytokine Signaling Pathways and Interactions (11 papers), Prostate Cancer Treatment and Research (6 papers) and Microbial Natural Products and Biosynthesis (4 papers). Rebecka Hellsten collaborates with scholars based in Sweden, United States and Spain. Rebecka Hellsten's co-authors include Anders Bjartell, Martin Johansson, Olov Sterner, Agnieszka Krzyzanowska, Susan Evans‐Axelsson, Anna Dahlman, Giacomo Canesin, Tommy Andersson, Karin Leandersson and Nishtman Dizeyi and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Scientific Reports.

In The Last Decade

Rebecka Hellsten

22 papers receiving 646 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecka Hellsten Sweden 14 324 310 195 122 106 23 649
Maria Nunes Portugal 6 267 0.8× 204 0.7× 96 0.5× 92 0.8× 41 0.4× 8 576
Junjie Piao China 20 208 0.6× 676 2.2× 153 0.8× 265 2.2× 60 0.6× 40 956
Sara G. Manore United States 9 256 0.8× 313 1.0× 82 0.4× 126 1.0× 77 0.7× 13 579
Maria Grazia Prisco Italy 16 316 1.0× 310 1.0× 79 0.4× 117 1.0× 59 0.6× 22 761
Elisa Brighenti Italy 10 250 0.8× 373 1.2× 57 0.3× 104 0.9× 50 0.5× 15 567
Wei Jing China 16 269 0.8× 341 1.1× 199 1.0× 111 0.9× 47 0.4× 45 694
Jun-Ying Zhou United States 11 186 0.6× 584 1.9× 56 0.3× 181 1.5× 111 1.0× 11 749
Kika Anyiwe Canada 5 183 0.6× 410 1.3× 78 0.4× 178 1.5× 60 0.6× 6 681
Zongzhen Xu China 17 190 0.6× 475 1.5× 235 1.2× 429 3.5× 49 0.5× 25 803
Emily K. Kleczko United States 14 249 0.8× 435 1.4× 249 1.3× 143 1.2× 152 1.4× 22 746

Countries citing papers authored by Rebecka Hellsten

Since Specialization
Citations

This map shows the geographic impact of Rebecka Hellsten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecka Hellsten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecka Hellsten more than expected).

Fields of papers citing papers by Rebecka Hellsten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecka Hellsten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecka Hellsten. The network helps show where Rebecka Hellsten may publish in the future.

Co-authorship network of co-authors of Rebecka Hellsten

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecka Hellsten. A scholar is included among the top collaborators of Rebecka Hellsten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecka Hellsten. Rebecka Hellsten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hellsten, Rebecka, Agnieszka Krzyzanowska, Margareta Persson, et al.. (2024). pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy. The Prostate. 85(3). 252–264.
2.
Hellsten, Rebecka, et al.. (2022). Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal compartment of localized hormone-naïve prostate cancer. Pathology - Research and Practice. 232. 153811–153811. 3 indexed citations
3.
Hellsten, Rebecka, et al.. (2022). The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells. Translational Oncology. 24. 101495–101495. 7 indexed citations
4.
Witt, Kristina, Susan Evans‐Axelsson, Andreas Lundqvist, et al.. (2021). Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. Cancer Immunology Immunotherapy. 70(11). 3155–3166. 24 indexed citations
5.
Canesin, Giacomo, Agnieszka Krzyzanowska, Rebecka Hellsten, & Anders Bjartell. (2020). Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer: overview and therapeutic opportunities. Current Opinion in Endocrine and Metabolic Research. 10. 36–42. 10 indexed citations
6.
Canesin, Giacomo, Héctor R. Contreras, Enrique A. Castellón, et al.. (2020). STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population. Scientific Reports. 10(1). 13958–13958. 22 indexed citations
7.
Canesin, Giacomo, Susan Evans‐Axelsson, Rebecka Hellsten, et al.. (2017). Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS ONE. 12(9). e0184418–e0184418. 64 indexed citations
8.
Coleman, Ilsa M., Peter S. Nelson, Roy Ehrnström, et al.. (2016). Expression of STAT3 in Prostate Cancer Metastases. European Urology. 71(3). 313–316. 83 indexed citations
9.
10.
Johansson, Martin, et al.. (2016). N-Conjugate prodrugs of galiellalactone. Tetrahedron Letters. 57(36). 4090–4093. 2 indexed citations
11.
Villoutreix, Bruno O., Sophie Lehn, Rebecka Hellsten, et al.. (2015). Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors. Molecular Cancer Research. 13(7). 1073–1082. 14 indexed citations
12.
Canesin, Giacomo, Susan Evans‐Axelsson, Rebecka Hellsten, et al.. (2015). The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer. European Urology. 69(3). 400–404. 40 indexed citations
13.
Johansson, Martin, et al.. (2014). Synthesis of Biotinylated Galiellalactone Analogues. International Journal of Organic Chemistry. 4(4). 225–235. 5 indexed citations
14.
Pérez, Moisés, Juan A. Collado, Rebecka Hellsten, et al.. (2014). The fungal metabolite galiellalactone interferes with the nuclear import of NF-κB and inhibits HIV-1 replication. Chemico-Biological Interactions. 214. 69–76. 10 indexed citations
15.
Johansson, Martin, Sven Kjellström, Víctor García, et al.. (2014). Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells. Journal of Biological Chemistry. 289(23). 15969–15978. 75 indexed citations
16.
Hellsten, Rebecka, Martin Johansson, Anna Dahlman, Olov Sterner, & Anders Bjartell. (2011). Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells. PLoS ONE. 6(7). e22118–e22118. 72 indexed citations
17.
Wegiel, Barbara, Susan Evans‐Axelsson, Rebecka Hellsten, et al.. (2010). Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer. Current Cancer Drug Targets. 10(4). 392–401. 24 indexed citations
18.
Valtonen‐André, Camilla, Anders Bjartell, Rebecka Hellsten, et al.. (2007). A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue. Biological Chemistry. 388(3). 289–95. 18 indexed citations
19.
Hellsten, Rebecka, Martin Johansson, Anna Dahlman, et al.. (2007). Galiellalactone is a novel therapeutic candidate against hormone‐refractory prostate cancer expressing activated Stat3. The Prostate. 68(3). 269–280. 62 indexed citations
20.
Hellsten, Rebecka, Martin Johansson, Olov Sterner, & Anders Bjartell. (2006). GALIELLALACTONE INHIBITS GROWTH OF PROSTATE CANCER CELL XENOGRAFTS AND INDUCES APOPTOSIS OF HUMAN PROSTATE CANCER CELLS EXPRESSING ACTIVE STAT3. European Urology Supplements. 5(14). 797–797. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Nunes Breakdown of academic impact, for papers by Junjie Piao Breakdown of academic impact, for papers by Sara G. Manore Breakdown of academic impact, for papers by Maria Grazia Prisco Breakdown of academic impact, for papers by Elisa Brighenti Breakdown of academic impact, for papers by Wei Jing Breakdown of academic impact, for papers by Jun-Ying Zhou Breakdown of academic impact, for papers by Kika Anyiwe Breakdown of academic impact, for papers by Zongzhen Xu Breakdown of academic impact, for papers by Emily K. Kleczko
Rankless by CCL
2026